157 related articles for article (PubMed ID: 26092192)
21. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status in invasive breast cancer: a 3,198 cases study at National Cancer Center, China.
Zhu X; Ying J; Wang F; Wang J; Yang H
Breast Cancer Res Treat; 2014 Oct; 147(3):551-5. PubMed ID: 25234844
[TBL] [Abstract][Full Text] [Related]
22. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
[TBL] [Abstract][Full Text] [Related]
23. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer.
Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K
Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397
[TBL] [Abstract][Full Text] [Related]
24. Molecular and Clinical Portrait of HER2-low Invasive Lobular Carcinomas.
Djerroudi L; El Sabeh-Ayoun A; Benoist C; Pierron G; Masliah-Planchon J; Fuhrmann L; Kieffer Y; Carton M; Ramtohul T; Callens C; Renault V; Bidard FC; Mechta-Grigoriou F; Vincent-Salomon A
Mod Pathol; 2024 May; 37(5):100463. PubMed ID: 38428737
[TBL] [Abstract][Full Text] [Related]
25. Biomarker profile of invasive lobular carcinoma: pleomorphic versus classic subtypes, clinicopathological characteristics and prognosis analyses.
Zhang Y; Luo X; Chen M; Yang L; Lei T; Pu T; Wei B; Bu H; Zhang Z
Breast Cancer Res Treat; 2022 Jul; 194(2):279-295. PubMed ID: 35666367
[TBL] [Abstract][Full Text] [Related]
26. ESPL1 is a candidate oncogene of luminal B breast cancers.
Finetti P; Guille A; Adelaide J; Birnbaum D; Chaffanet M; Bertucci F
Breast Cancer Res Treat; 2014 Aug; 147(1):51-9. PubMed ID: 25086634
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases.
Bhargava R; Beriwal S; Dabbs DJ; Ozbek U; Soran A; Johnson RR; Brufsky AM; Lembersky BC; Ahrendt GM
Cancer; 2010 Mar; 116(6):1431-9. PubMed ID: 20131351
[TBL] [Abstract][Full Text] [Related]
28. The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast cancer: a prospective study.
Tong LC; Nelson N; Tsourigiannis J; Mulligan AM
Am J Surg Pathol; 2011 Apr; 35(4):545-52. PubMed ID: 21358301
[TBL] [Abstract][Full Text] [Related]
29. Expression profiling of breast tumors based on human epidermal growth factor receptor 2 status defines migration-related genes.
Cuadros M; Cano C; López FJ; López-Castro R; Concha A
Pathobiology; 2013; 80(1):32-40. PubMed ID: 22832278
[TBL] [Abstract][Full Text] [Related]
30. Id4 messenger RNA and estrogen receptor expression: inverse correlation in human normal breast epithelium and carcinoma.
de Candia P; Akram M; Benezra R; Brogi E
Hum Pathol; 2006 Aug; 37(8):1032-41. PubMed ID: 16867866
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of biomarkers in multifocal/multicentric invasive breast carcinomas.
Pekmezci M; Szpaderska A; Osipo C; Erşahin Ç
Int J Surg Pathol; 2013 Apr; 21(2):126-32. PubMed ID: 23204031
[TBL] [Abstract][Full Text] [Related]
32. Discordant HER2 status between primary breast carcinoma and recurrent/metastatic tumors using fluorescence in situ hybridization on cytological samples.
Arihiro K; Oda M; Ogawa K; Tominaga K; Kaneko Y; Shimizu T; Matsumoto S; Oda M; Kurita Y; Taira Y
Jpn J Clin Oncol; 2013 Jan; 43(1):55-62. PubMed ID: 23225912
[TBL] [Abstract][Full Text] [Related]
33. Oestrogen receptor/progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer: a 9-year study at Princess Noorah Oncology Center, Saudi Arabia.
Satti MB
Histopathology; 2011 Sep; 59(3):537-42. PubMed ID: 21668473
[TBL] [Abstract][Full Text] [Related]
34. Ductal invasive mammary carcinoma--clinicopathological prognostic factors related to immunohistochemical expression of hormonal receptors and Her2/neu oncoprotein.
Recăreanu F; Simionescu C; Georgescu CV; Pirici E
Rom J Morphol Embryol; 2011; 52(3 Suppl):1059-64. PubMed ID: 22119825
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical characterization of molecular subtypes of invasive breast cancer: a study from North India.
Verma S; Bal A; Joshi K; Arora S; Singh G
APMIS; 2012 Dec; 120(12):1008-19. PubMed ID: 23030684
[TBL] [Abstract][Full Text] [Related]
36. Immunochemistry for oestrogen receptor, progesterone receptor and HER2 on cell blocks in primary breast carcinoma.
Kumar SK; Gupta N; Rajwanshi A; Joshi K; Singh G
Cytopathology; 2012 Jun; 23(3):181-6. PubMed ID: 21375607
[TBL] [Abstract][Full Text] [Related]
37. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
Brown M; Bauer K; Pare M
Breast Cancer Res Treat; 2010 Feb; 120(1):217-27. PubMed ID: 19629680
[TBL] [Abstract][Full Text] [Related]
38. Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapy.
Wong H; Lau S; Cheung P; Wong TT; Parker A; Yau T; Epstein RJ
BMC Cancer; 2014 Nov; 14():826. PubMed ID: 25385074
[TBL] [Abstract][Full Text] [Related]
39. The hormone receptor, human epidermal growth factor receptor 2, and molecular subtype status of individual tumor foci in multifocal/multicentric invasive ductal carcinoma of breast.
Choi Y; Kim EJ; Seol H; Lee HE; Jang MJ; Kim SM; Kim JH; Kim SW; Choe G; Park SY
Hum Pathol; 2012 Jan; 43(1):48-55. PubMed ID: 21733550
[TBL] [Abstract][Full Text] [Related]
40. Cyclin D1 overexpression associates with favourable prognostic factors in invasive breast carcinoma.
El-Hafez AA; El Aaty Shawky A; Hasan B
Cancer Biomark; 2012; 12(4):149-54. PubMed ID: 23568005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]